Prostate Cancer - Results from #720

Systemic Treatments for Metastatic Prostate Cancer in 2024. August 12, 2024

The Sensitivity and Specificity of Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Predicting Seminal Vesicle Invasion in Clinically Significant Prostate Cancer: A Mult August 12, 2024

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. August 12, 2024

Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. August 12, 2024

Controversies in prostate cancer screening. August 12, 2024

Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer. August 9, 2024

External Validation of Stockholm3 in a Retrospective German Clinical Cohort. August 9, 2024

Outcomes after laser enucleation of the prostate with and without significant storage symptoms. August 9, 2024

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. August 9, 2024

MYBL2 Drives Prostate Cancer Plasticity: Inhibiting its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. August 9, 2024

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). August 9, 2024

Prevention of Device-Related Infections in Patients with Cancer: Current Practice and Future Horizons August 8, 2024

Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control. August 8, 2024

Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer. August 8, 2024

Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study. August 8, 2024

Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients. August 8, 2024

Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. August 8, 2024

Harnessing artificial intelligence for prostate cancer management. August 8, 2024

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. August 8, 2024

A Phase 1b Dose Escalation Study of FOR46, a Novel Antibody-Drug Conjugate Targeting a Tumor-Specific Epitope of CD46, in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer August 7, 2024

Page 37 of 1450